✦ LIBER ✦

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma : A Gynecologic Oncology Group study

✍ Scribed by Kristin K. Zorn; Chunqiao Tian; William P. McGuire; William J. Hoskins; Maurie Markman; Franco M. Muggia; Peter G. Rose; Robert F. Ozols; David Spriggs; Deborah K. Armstrong

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 232 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24084

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Responsiveness of patients with advanced

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patients

✍ Kenneth D. Hatch; Jackson B. Beecham; John A. Blessing; William T. Creasman 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 2 views

CA-125 change after chemotherapy in pred

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers : A Gynecologic Oncology Group study

✍ Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F. Ozols; William P. McGuir 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

Association between serum levels of solu

Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy : A Gynecologic Oncology Group study

✍ Robert A. Burger; Kathleen M. Darcy; Philip J. DiSaia; Bradley J. Monk; Elizabet 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

## Abstract ## BACKGROUND A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics

Distribution of HER-2 overexpression in

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma : From the Danish “MALOVA” Ovarian Cancer Study

✍ Estrid V. S. Høgdall; Lise Christensen; Susanne K. Kjaer; Jan Blaakaer; Johannes 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 2 views

## Abstract ## BACKGROUND The HER‐2 (Human Epidermal Growth factor receptor‐2, also known as c‐__erb__‐2/__neu__) protooncogene encodes a transmembrane receptor protein, __M__~r~ 185,000. Studies have shown that the HER‐2 oncogene is overexpressed in approximately 25–30% of ovarian carcinoma (OC)

Cis-platinum in treatment of advanced or

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group

✍ Tate Thigpen; Hugh Shingleton; Howard Homesley; Leo Lagasse; John Blessing 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 3 views

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested